SCIENTIFIC OPINION

Scientific Opinion on the substantiation of a health claim related to thiamin and maintenance of normal neurological development and function pursuant to Article 14 of Regulation (EC) No 1924/2006

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)\(^2,3\)

European Food Safety Authority (EFSA), Parma, Italy

ABSTRACT

Following an application from HiPP GmbH submitted pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of Germany, the Panel on Dietetic Products, Nutrition and Allergies was asked to deliver an opinion on the scientific substantiation of a health claim related to thiamin and maintenance of normal neurological development and function. Thiamin is a well recognised nutrient and is measurable in foods by established methods. Thiamin is considered to be sufficiently characterised. Maintenance of normal neurological development and function is considered to be a beneficial physiological effect. It is well recognised that the clinical signs of thiamin deficiency include mental changes, such as apathy, decrease in short-term memory, confusion and irritability as well as polyneuritis and paralysis of the peripheral nerves. All essential nutrients, including vitamins and minerals, are required for normal development of infants and children. The Panel concludes that a cause and effect relationship has been established between the dietary intake of thiamin and maintenance of normal neurological development and function. The following wording reflects the scientific evidence: “Thiamin contributes to the maintenance of normal neurological development and function.” The target population is infants and children up to 3 years. © European Food Safety Authority, 2011

KEY WORDS

Thiamin, infants, children, neurological function, development, health claims.

---

\(^1\) On request from the from the Competent Authority of Germany following an application by HiPP GmbH, Question No EFSA-Q-2009-00455, adopted on 28 January 2011.

\(^2\) Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, Pagona Lagiou, Martinus Lavik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, Hendrik van Loveren and Hans Verhagen. Correspondence: nda@efsa.europa.eu

\(^3\) Acknowledgement: The Panel wishes to thank the members of the Working Group on Claims for the preparatory work on this scientific opinion: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Marina Heinonen, Hannu Korhonen, Martinus Lavik, Ambroise Martin, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Inge Tetens, Hendrik van Loveren and Hans Verhagen.


© European Food Safety Authority, 2011
SUMMARY
Following an application from HiPP GmbH submitted pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of Germany, the Panel on Dietetic Products, Nutrition and Allergies was asked to deliver an opinion on the scientific substantiation of a health claim related to thiamin and maintenance of normal neurological development and function.

The scope of the application was proposed to fall under a health claim referring to children’s development and health.

The food constituent, which is the subject of the health claim, is thiamin. Thiamin is a well recognised nutrient and is measurable in foods by established methods. The Panel considers that thiamin is sufficiently characterised.

The claimed effect is “thiamin in the diet is necessary for the normal development and function of the neurological system”. The proposed target population for the health claim is children from birth to three years. The Panel considers that maintenance of normal neurological development and function is a beneficial physiological effect.

The applicant identified two human intervention studies, seven observational studies, three reviews and one medical position paper on the composition of infant formulae, four opinions of authoritative/scientific bodies and five textbook chapters as pertinent to the claim.

It is well recognised that the clinical signs of thiamin deficiency include mental changes, such as apathy, decrease in short-term memory, confusion and irritability as well as polyneuritis and paralysis of the peripheral nerves. Manifestations are seen in the autonomic, the sensory and the motor systems.

The Panel notes that all essential nutrients, including vitamins and minerals, are required for normal development of infants and children.

The Panel also notes that the role of thiamin in normal neurological function is not specific to any population group.

The Panel concludes that a cause and effect relationship has been established between the dietary intake of thiamin and maintenance of normal neurological development and function.

The Panel considers that the following wording reflects the scientific evidence: “Thiamin contributes to the maintenance of normal neurological development and function.”

The Panel considers that, in order to bear the claim, follow-on formulae should comply with the criteria of composition of follow-on formulae as laid down in Directive 2006/141/EC; nutritionally complete foods for special medical purposes intended for use by infants and nutritionally complete foods for special medical purposes other than those intended for use by infants should comply with the criteria of composition of these foods as laid down in Directive 1999/21/EC; processed cereal-based foods for infants and young children should comply with the criteria of composition of these foods as laid down in Directive 2006/125/EC; other foodstuffs intended for infants and young children should provide at least 15 % of the reference values for nutrition labelling for foods intended for infants and young children as laid down in Directive 2006/125/EC. Such amounts can be easily consumed as part of a balanced diet. The target population is infants and children up to 3 years.
TABLE OF CONTENTS

Abstract ................................................................................................................................. 1
Summary ................................................................................................................................. 2
Table of contents .................................................................................................................. 3
Background as provided by the European Commission .......................................................... 4
Terms of reference as provided by the European Commission .............................................. 4
EFSA Disclaimer ................................................................................................................... 4
Information provided by the applicant .................................................................................. 5
Assessment ............................................................................................................................ 6
1. Characterisation of the food/constituent ......................................................................... 6
2. Relevance of the claimed effect to human health ............................................................... 6
3. Scientific substantiation of the claimed effect ................................................................. 6
4. Panel’s comments on the proposed wording .................................................................... 7
5. Conditions and restrictions of use .................................................................................. 7
Conclusions ......................................................................................................................... 7
Documentation provided to EFSA ....................................................................................... 8
References ............................................................................................................................ 8
BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION

Regulation (EC) No 1924/2006 harmonises the provisions that relate to nutrition and health claims and establishes rules governing the Community authorisation of health claims made on foods. As a rule, health claims are prohibited unless they comply with the general and specific requirements of that Regulation and are authorised in accordance with this Regulation and included in the lists of authorised claims provided for in Articles 13 and 14 thereof. In particular, Articles 14 to 17 of that Regulation lay down provisions for the authorisation and subsequent inclusion of reduction of disease risk claims and claims referring to children’s development and health in a Community list of permitted claims.

According to Article 15 of that Regulation, an application for authorisation shall be submitted by the applicant to the national competent authority of a Member State, who will make the application and any supplementary information supplied by the applicant available to the European Food Safety Authority (EFSA).

STEPS TAKEN BY EFSA:

- The application was received on 04/03/2009.
- The scope of the application was proposed to fall under a health claim referring to children’s development and health.
- During the check for completeness of the application, the applicant was requested to provide missing information on 08/04/2009.
- The applicant provided the missing information on 16/09/2010.
- The scientific evaluation procedure started on 30/09/2010.
- During the meeting on 28/01/2011, the NDA Panel, after having evaluated the overall data submitted, adopted an opinion on the scientific substantiation of a health claim related to thiamin and maintenance of normal neurological development and function.

TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION

EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with Article 16 of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an opinion on the scientific substantiation of a health claim related to thiamin and maintenance of normal neurological development and function.

EFSA DISCLAIMER

The present opinion does not constitute and cannot be construed as an authorisation to the marketing of thiamin, a positive assessment of its safety, nor a decision on whether thiamin is, or is not, classified as a foodstuff. It should be noted that such an assessment is not foreseen in the framework of Regulation (EC) No 1924/2006.

It should also be highlighted that the scope, the proposed wording of the claim and the conditions of use as proposed by the applicant may be subject to changes pending the outcome of the authorisation procedure foreseen in Article 17 of Regulation (EC) No 1924/2006.

---


5 In accordance with EFSA “Scientific and Technical guidance for the Preparation and Presentation of the Application for Authorisation of a Health Claim”.

INFORMATION PROVIDED BY THE APPLICANT

**Applicant’s name and address:** HiPP GmbH & Co. Vertrieb KG, Georg-Hipp-Straße 7, 85276 Pfaffenhofen, Germany.

**Food/constituent as stated by the applicant**

According to the applicant the food constituent for which the claim is made is thiamin (vitamin B1).

**Health relationship as claimed by the applicant**

According to the applicant, a minimum level of thiamin in the diet is necessary for the normal development and function of the neurological system. For children in particular, the neurological system dramatically develops and evolves in the first years of life and an adequate level of thiamin is required for normal growth and development of infants and young children.

**Wording of the health claim as proposed by the applicant**

The applicant proposed the following wording for the health claim: “Vitamin B1 for development of the nervous system”

As equivalent wording the following wording is proposed by the applicant: “Vitamin B1/thiamin contributes to/participates to/plays an important role for/is important for/is involved in/is necessary for/ is needed for the function/normal function/normal development of the nervous system.”

**Specific conditions of use as proposed by the applicant**

According to the applicant, the target population is infants and young children from birth to 3 years of age as defined in Directive 89/398/EEC on foodstuffs intended for particular nutritional uses. The claim should be used on foods that are exclusively intended for the category of infants and young children and in line with the composition laid down in the specific directives (Directive 2006/141/EC; Directive 2006/125/EC; Directive 1999/21/EC).

According to the applicant the quantity needed to achieve claimed effect is:

- For follow-on formulae, the content in thiamin should be within the range set in the Directive 2006/141/EC.
- For dietary foods for special medical purposes (FSMP), the content in thiamin should be within the range set in the Directive 1999/21/EC.
- For processed cereal-based foods, the content in thiamin should be within the range set in the Directive 2006/125/EC.
- For baby foods, the content in thiamin should be at least reach 15 % of the Nutrient Reference Value (NRV) set in the Directive 2006/125/EC.
- For other dietary foods intended for infants and young children, the content in thiamin should at least reach 15% of the NRV set in the Directive 2006/141/EC.
ASSESSMENT

1. Characterisation of the food/constituent

The food constituent that is the subject of the health claim is thiamin. Thiamin is a well recognised nutrient and is measurable in foods by established methods.


The Panel considers that the food constituent, thiamin, which is the subject of the health claim, is sufficiently characterised.

2. Relevance of the claimed effect to human health

The claimed effect is “thiamin in the diet is necessary for the normal development and function of neurological system”. The proposed target population for the health claim is children from birth to three years.

The Panel considers that maintenance of normal neurological development and function is a beneficial physiological effect.

3. Scientific substantiation of the claimed effect

The applicant identified two human intervention studies, seven observational studies, three reviews and one medical position paper on the composition of infant formulae, four opinions of authoritative/scientific bodies and five textbook chapters as pertinent to the claim. The literature search strategy has been described.

It is well recognised that the clinical signs of thiamin deficiency include mental changes, such as apathy, decrease in short-term memory, confusion and irritability (IoM, 1998) as well as polyneuritis and paralysis of the peripheral nerves. Manifestations are seen in the autonomic, the sensory and the motor systems (WHO, 1999).

The Panel notes that all essential nutrients, including vitamins and minerals, are required for normal development of infants and children.

The Panel has already addressed the role of thiamin in the normal function of the nervous system for the general population with a favourable outcome in a previous opinion under Article 13(1) of Regulation (EC) No 1924/2006 (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2009) and it notes that the role of thiamin in normal neurological function is not specific to any population group.

The Panel concludes that a cause and effect relationship has been established between the dietary intake of thiamin and maintenance of normal neurological development and function.

4. **Panel’s comments on the proposed wording**

The Panel considers that the following wording reflects the scientific evidence: “Thiamin contributes to the maintenance of normal neurological development and function.”

5. **Conditions and restrictions of use**

The Panel considers that, in order to bear the claim

- follow-on formulae should comply with the criteria of composition of follow-on formulae as laid down in Directive 2006/141/EC;
- nutritionally complete foods for special medical purposes intended for use by infants and nutritionally complete foods for special medical purposes other than those intended for use by infants should comply with the criteria of composition of these foods as laid down in Directive 1999/21/EC;  
- processed cereal-based foods for infants and young children should comply with the criteria of composition of these foods as laid down in Directive 2006/125/EC;
- other foodstuffs intended for infants and young children should provide at least 15% of the reference values for nutrition labelling for foods intended for infants and young children as laid down in Directive 2006/125/EC;

Such amounts can be easily consumed as part of a balanced diet. The target population is infants and children up to 3 years. Tolerable Upper Intake Levels (UL) have not been established for thiamin in children, adolescents and adults (SCF, 2001).

**CONCLUSIONS**

On the basis of the data presented, the Panel concludes that:

- The food constituent, thiamin, which is the subject of the health claim, is sufficiently characterised.
- The claimed effect is “thiamin in the diet is necessary for the normal development and function of the neurological system”. The proposed target population for the health claim is children from birth to three years. Maintenance of normal neurological development and function is a beneficial physiological effect.
- A cause and effect relationship has been established between the dietary intake of thiamin and maintenance of normal neurological development and function.
- The following wording reflects the scientific evidence: “Thiamin contributes to the maintenance of normal neurological development and function.”
- In order to bear the claim follow-on formulae should comply with the criteria of composition of follow-on formulae as laid down in Directive 2006/141/EC; nutritionally complete foods for special medical purposes intended for use by infants and nutritionally complete foods for special medical purposes other than those intended for use by infants should comply with the criteria of composition of these foods as laid down in Directive 1999/21/EC; processed cereal-

---

based foods for infants and young children should comply with the criteria of composition of these foods as laid down in Directive 2006/125/EC; other foodstuffs intended for infants and young children should provide at least 15% of the reference values for nutrition labelling for foods intended for infants and young children as laid down in Directive 2006/125/EC. Such amounts can be easily consumed as part of a balanced diet. The target population is infants and children up to 3 years.

**DOCUMENTATION PROVIDED TO EFSA**

Health claim application on thiamin and maintenance of normal neurological development and function pursuant to Article 14 of Regulation (EC) No 1924/2006 (Claim serial No: 0243_DE). September 2010. Submitted by HiPP GmbH.

**REFERENCES**


